[Ebastine in the treatment of seasonal allergic rhinitis].
OBJECTIVE
To test the efficiency and tolerance of the second generation antihistamine drug ebastin (kestine) in patients with seasonal allergic rhinitis (SAR).


METHODS
Kestin was given for 3 weeks in doses 10 and 20 mg/day to 226 patients with SAR running for 6.8 +/- 6.1 years. SAR symptoms relief, subjective effects, side effects were studied.


RESULTS
The total index of rhinitis symptoms diminished from 11.6 to 1.2 scores. Subjective response was registered in 82% of the patients, objective in 77%. Neither treatment aggravations nor serious side effects occurred. 2 patients had drowsiness, head aches, dizziness and discontinued treatment.


CONCLUSIONS
Kestin is effective in SAR, had no serious side effects, is well tolerated.
Il'ina
N I
NI
Balabolkin
I I
II
Blokhin
B M
BM
Goriachkina
L A
LA
Kolganova
N A
NA
Pampura
A N
AN
Sidorenko
I V
IV
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002090:Butyrophenones / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D016896:Treatment Outcome
D002090:Butyrophenones; D006634:Histamine H1 Antagonists; D010880:Piperidines; C058249:ebastine
Ebastin pri lechenii sezonnogo allergicheskogo rinita.